

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

April 29, 2022

Adenosine Injection 3 mg/mL Allocation Notice

Dear Valued Customer.

Fresenius Kabi Canada regrets to advise that due to a production delay our **Adenosine 3 mg/mL SD Vial 2 mL** will be placed on a reduced allocation effective **May 1, 2022**. Contract customers will be allocated **40% of historical monthly demand**.

During this time, our Adenosine Injection 3 mg/mL prefilled syringe 2 mL and 4 mL will also be placed on allocation. Our 2 mL syringe will be used to cover 100% of historical monthly 2 mL syringe demand plus 60% of historical monthly 2 mL vial demand. Our 4 mL syringe will be placed on 100% allocation. Contract customers will be allocated 100% of historical monthly demand.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Supply Status May 2022
02267659	C605102	937071	192880	Adenosine Injection 3 mg/mL SD Vial 2 mL	40% Allocation
02457474	K051002	970852	115670	Adenosine Injection 3 mg/mL prefilled syringe 2 mL	Allocation to cover 100% of 2 mL syringe demand plus 60% of 2 mL vial demand
02457482	K051004	970864	115606	Adenosine Injection 3 mg/mL prefilled syringe 4 mL	100% Allocation

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

George Shamsoun

Associate Director – Marketing, IV Drugs george.shamsoun@fresenius-kabi.com